Synthetic oxadiazole-containing compounds have a wide range of pharmacological effects, including analgesic, antibacterial, antitubercular, antioedema, anti-inflammatory, and anticonvulsant properties. One of the major public health issues of the twenty-first century is the prevalence of type 2 diabetes, which is rising in both developed and developing nations. Pharmaceuticals used to treat diabetes often contain a number of compounds with heterocyclic rings. The oxadiazole derivatives belong to the heterocyclic family and have numerous promising pharmaceutical uses. Very few studies have been done on the anti-diabetic properties of synthetic oxadiazole derivatives. The current study was conducted with the main aim of determination of in-vitro antidiabetic activities of synthetic oxadiazole derivatives. Three commercially available synthetic oxadiazole derivatives (SODZs) viz. SODZ1, SODZ2, and SOD3 were determined for in-vitro antidiabetic activity by alpha-glucosidase inhibitory activity method. Results revealed that SODZ1 showed significant inhibition for alpha-glucosidase enzyme. SODZ1 exhibited high percentage inhibition (37.97%) and the IC50 value of SODZ1 was found to be 48.12μg which was comparable with that of the IC50 value of standard acarbose (31.23μg). In conclusion, SOZD1 was proved to probable drug molecule for the treatment of diabetes.